Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement

Purpose of review: Due to the findings of current studies and the approval of novel substances for the therapy of hormone-receptor-positive breast cancer patients, the established standards of endocrine treatment are changing. The purpose of this review is to give an overview of the history of endoc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Naiba Nabieva, Peter A. Fasching
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	breast cancer endocrine treatment tamoxifen aromatase inhibitor fulvestrant CDK 4/6 inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b2660c6df8e646dcb828390fda321e7e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b2660c6df8e646dcb828390fda321e7e
record_format	dspace
spelling	oai:doaj.org-article:b2660c6df8e646dcb828390fda321e7e2021-11-25T17:02:04ZEndocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement10.3390/cancers132256432072-6694https://doaj.org/article/b2660c6df8e646dcb828390fda321e7e2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5643https://doaj.org/toc/2072-6694Purpose of review: Due to the findings of current studies and the approval of novel substances for the therapy of hormone-receptor-positive breast cancer patients, the established standards of endocrine treatment are changing. The purpose of this review is to give an overview of the history of endocrine treatment, to clarify its role in the present standard of care, and to discuss the possibilities of improvement. Recent findings: Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that have been used for decades in the therapy of hormone-receptor-positive breast cancer patients. However, since a relevant number of women suffer at some point from disease recurrence or progression, several novel substances are being investigated to overcome resistance mechanisms by interfering with certain signaling pathways, such as the PI3K/AKT/mTOR or the CDK4/6 pathways. mTOR and CDK4/6 inhibitors were the first drugs approved for this purpose and many more are in development. Summary: Endocrine treatment is one of the best tolerable cancer therapies available. Continuous investigation serves to improve patients’ outcomes and modernize the current standard of care. Considering the resistance mechanisms and substances analyzed against these, endocrine treatment of hormone-receptor-positive breast cancer is on the brink of a new era.Naiba NabievaPeter A. FaschingMDPI AGarticlebreast cancerendocrine treatmenttamoxifenaromatase inhibitorfulvestrantCDK 4/6 inhibitorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5643, p 5643 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer endocrine treatment tamoxifen aromatase inhibitor fulvestrant CDK 4/6 inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer endocrine treatment tamoxifen aromatase inhibitor fulvestrant CDK 4/6 inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Naiba Nabieva Peter A. Fasching Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
description	Purpose of review: Due to the findings of current studies and the approval of novel substances for the therapy of hormone-receptor-positive breast cancer patients, the established standards of endocrine treatment are changing. The purpose of this review is to give an overview of the history of endocrine treatment, to clarify its role in the present standard of care, and to discuss the possibilities of improvement. Recent findings: Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that have been used for decades in the therapy of hormone-receptor-positive breast cancer patients. However, since a relevant number of women suffer at some point from disease recurrence or progression, several novel substances are being investigated to overcome resistance mechanisms by interfering with certain signaling pathways, such as the PI3K/AKT/mTOR or the CDK4/6 pathways. mTOR and CDK4/6 inhibitors were the first drugs approved for this purpose and many more are in development. Summary: Endocrine treatment is one of the best tolerable cancer therapies available. Continuous investigation serves to improve patients’ outcomes and modernize the current standard of care. Considering the resistance mechanisms and substances analyzed against these, endocrine treatment of hormone-receptor-positive breast cancer is on the brink of a new era.
format	article
author	Naiba Nabieva Peter A. Fasching
author_facet	Naiba Nabieva Peter A. Fasching
author_sort	Naiba Nabieva
title	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
title_short	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
title_full	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
title_fullStr	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
title_full_unstemmed	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
title_sort	endocrine treatment for breast cancer patients revisited—history, standard of care, and possibilities of improvement
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b2660c6df8e646dcb828390fda321e7e
work_keys_str_mv	AT naibanabieva endocrinetreatmentforbreastcancerpatientsrevisitedhistorystandardofcareandpossibilitiesofimprovement AT peterafasching endocrinetreatmentforbreastcancerpatientsrevisitedhistorystandardofcareandpossibilitiesofimprovement
_version_	1718412796743385088

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement

Ejemplares similares